<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0020115"><a href="http://purl.obolibrary.org/obo/MONDO_0020115">MONDO:0020115</a></h3>
<p><strong>Label:</strong> secondary polycythemia</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0016540">MONDO:0016540</a> (congenital secondary polycythemia), <a href="http://purl.obolibrary.org/obo/MONDO_0016599">MONDO:0016599</a> (autosomal dominant secondary polycythemia), <a href="http://purl.obolibrary.org/obo/MONDO_0016541">MONDO:0016541</a> (acquired secondary polycythemia),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://www.orpha.net/ORDO/Orphanet_247511">Orphanet:247511</a>, <a href="http://purl.obolibrary.org/obo/OMIM_609820">OMIM:609820</a>, <a href="http://www.orpha.net/ORDO/Orphanet_238547">Orphanet:238547</a>, <a href="http://www.orpha.net/ORDO/Orphanet_238536">Orphanet:238536</a>, <a href="http://purl.obolibrary.org/obo/OMIM_611783">OMIM:611783</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0001900">HP:0001900</a> (Increased hemoglobin) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and <a href="http://purl.obolibrary.org/obo/HP_0001900">HP:0001900</a> (Increased hemoglobin) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000006">HP:0000006</a> (Autosomal dominant inheritance) and <a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000005">HP:0000005</a> (Mode of inheritance) and <a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and (not (<a href="http://purl.obolibrary.org/obo/HP_0100634">HP:0100634</a> (Neuroendocrine neoplasm))) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and (not (<a href="http://purl.obolibrary.org/obo/HP_0100570">HP:0100570</a> (Carcinoid tumor))) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and (not (<a href="http://purl.obolibrary.org/obo/HP_0100568">HP:0100568</a> (Neoplasm of the endocrine system))) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and (not (<a href="http://purl.obolibrary.org/obo/HP_0100007">HP:0100007</a> (Neoplasm of the peripheral nervous system))) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and (not (<a href="http://purl.obolibrary.org/obo/HP_0031440">HP:0031440</a> (Abnormal tricuspid valve morphology))) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and (not (<a href="http://purl.obolibrary.org/obo/HP_0031273">HP:0031273</a> (Shock))) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and (not (<a href="http://purl.obolibrary.org/obo/HP_0030956">HP:0030956</a> (Abnormality of cardiovascular system electrophysiology))) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and (not (<a href="http://purl.obolibrary.org/obo/HP_0030872">HP:0030872</a> (Abnormal cardiac ventricular function))) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and (not (<a href="http://purl.obolibrary.org/obo/HP_0030680">HP:0030680</a> (Abnormality of cardiovascular system morphology))) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and (not (<a href="http://purl.obolibrary.org/obo/HP_0030405">HP:0030405</a> (Pancreatic endocrine tumor))) 70.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001899">HP:0001899</a> (Increased hematocrit) and (not (<a href="http://purl.obolibrary.org/obo/HP_0030404">HP:0030404</a> (Glucagonoma))) 70.00%</li>
</ul>
</body>
</html>
